Monika Wissinger

Title: Monika Wissinger: Innovator in Pharmaceutical Compositions

Introduction

Monika Wissinger is a prominent inventor based in Gilching, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of bispecific single chain antibodies. With a total of 3 patents to her name, her work is paving the way for innovative treatments in oncology.

Latest Patents

Wissinger's latest patents focus on pharmaceutical compositions that exhibit resistance to soluble Carcinoembryonic Antigen (CEA). The disclosures detail a bispecific single chain antibody that binds specifically to human CD3 and human CEA. This innovative approach includes methods for treating epithelial tumors in humans using these pharmaceutical compositions. Additionally, the patents outline processes for producing these compositions and their medical uses, emphasizing the importance of the specific bispecific single chain antibody molecules that target both the human CD3 antigen and the human CEA antigen.

Career Highlights

Throughout her career, Monika Wissinger has worked with notable companies in the pharmaceutical industry. She has been associated with Amgen Research (Munich) GmbH and Micromet AG, where she has contributed her expertise in antibody development and pharmaceutical research. Her work has been instrumental in advancing therapeutic options for patients.

Collaborations

Wissinger has collaborated with esteemed colleagues, including Ralf Lutterbüse and Evelyne Schaller. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical sector.

Conclusion

Monika Wissinger's contributions to the field of pharmaceuticals, particularly through her innovative patents, highlight her role as a leading inventor. Her work continues to impact the development of effective treatments for cancer, showcasing the importance of innovation in healthcare.